Marconi relishes flurry of deals
Christmas came early for Marconi Medical Systems. In mid-December, the multimodality vendor completed back-to-back deals for equipment and supplies.A distribution agreement announced Dec. 19 will extend the existing relationship between Marconi Health
Christmas came early for Marconi Medical Systems. In mid-December, the multimodality vendor completed back-to-back deals for equipment and supplies.
A distribution agreement announced Dec. 19 will extend the existing relationship between Marconi Health Care Products (HCP) and leading group purchasing organization Novation. The three-year contract, which takes effect April 1, contains two one-year renewal options. Marconi estimates the potential for sales under the new agreement at more than $100 million annually. The deal also calls for Marconi HCP to connect its information systems to and offer its products through Marketplace @ Novation.
A day earlier, on Dec. 18, Marconi made public the signing of a $10 million contract to expand the University of Utah's existing PACS. The contract will add equipment and services for the University Health Sciences Center in Salt Lake City, as well as several outlying facilities in the University of Utah Health Network. The current system, consisting of Marconi technology dating back to 1997, has about 15 diagnostic workstations, an archive, and a beta version of Marconi's Web-based distribution system. Under the new agreement, this system will be expanded over the next year to include more than 40 workstations, a full Web distribution system, and a redundant archive, which will enable migration from the centralized system presently in use to a fully distributed architecture.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
